Combined Treatment With Chemotherapy and Adjuvant Radiation for Advanced-Stage HD
| Study (reference) . | Stage . | Treatment (cycles) . | Patients (no.) . | Follow-up (yr) . | CR (%) . | FFS (%) . | OS (%) . | Toxic Deaths (%) . |
|---|---|---|---|---|---|---|---|---|
| Milan71 72 | IIB, IIIA/B | MOPP/EFRT/MOPP (3 + 3) | 114 | 10 | 81 | 62 | 64 | 3 |
| ABVD/EFRT/ABVD (3 + 3) | 118 | 92 | 81 | 71 | 3 | |||
| Milan63 | IIA, B/bulky & III & IV | MOPP/ABVD (6-8) + RT (bulky) | 427 | 10 | 90 | 68 | 73 | 1 |
| Yale69 | IIIB & IV | MOPP, MVVPP or MOPP/ABVD + LDIF | 184 | 10 15 | 82 | 695-150 675-150 | 66 54 | |
| SKI70 | IIB/bulky III & IV | MOPP/ABVD (6-8) + LDIF | 270 | 10 | 82 | 70 | 74 | |
| SWOG73 5-151 | III, IV in CR | MOP-BAP (6) MOP-BAP (6) + LDIF | 130 104 | 5 | NA NA | 66 74 | 79 86 | |
| EORTC74 5-151 | III, IV in PR | MOPP/ABV (6) + LDIF | 122 | 3.5 | NA | 75 | 87 |
| Study (reference) . | Stage . | Treatment (cycles) . | Patients (no.) . | Follow-up (yr) . | CR (%) . | FFS (%) . | OS (%) . | Toxic Deaths (%) . |
|---|---|---|---|---|---|---|---|---|
| Milan71 72 | IIB, IIIA/B | MOPP/EFRT/MOPP (3 + 3) | 114 | 10 | 81 | 62 | 64 | 3 |
| ABVD/EFRT/ABVD (3 + 3) | 118 | 92 | 81 | 71 | 3 | |||
| Milan63 | IIA, B/bulky & III & IV | MOPP/ABVD (6-8) + RT (bulky) | 427 | 10 | 90 | 68 | 73 | 1 |
| Yale69 | IIIB & IV | MOPP, MVVPP or MOPP/ABVD + LDIF | 184 | 10 15 | 82 | 695-150 675-150 | 66 54 | |
| SKI70 | IIB/bulky III & IV | MOPP/ABVD (6-8) + LDIF | 270 | 10 | 82 | 70 | 74 | |
| SWOG73 5-151 | III, IV in CR | MOP-BAP (6) MOP-BAP (6) + LDIF | 130 104 | 5 | NA NA | 66 74 | 79 86 | |
| EORTC74 5-151 | III, IV in PR | MOPP/ABV (6) + LDIF | 122 | 3.5 | NA | 75 | 87 |
Abbreviations: PR, partial remission; EFRT, extended field radiation therapy; LDIF, low-dose involved field radiation therapy; RT (bulky), radiation therapy to bulky disease; SKI, Memorial/Sloan-Kettering Cancer Institute, SWOG, Southwestern Oncology Group; EORTC, European Organization for Research and Treatment of Cancer; MVVPP, (methclorethamine, vincristine, vinblastine, prednisone, procarbazine); MOP-BAP, (mechlorethamine, vincristine, prednisone, bleomycin, doxorubicin, procarbazine); NA, not applicable; see Table 4.
Progression-free survival.
All patients in CR after MOP-BAP (SWOG) or in PR after MOPP/ABV (EORTC). See text for details.